UBS Maintains Neutral on Harmony Biosciences Hldgs, Lowers Price Target to $36
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst So Youn Shim maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Neutral and lowers the price target from $46 to $36.
UBS analyst So Youn Shim maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Neutral and lowers the price target from $46 to $36.